SG Americas Securities
BDTX icon

SG Americas Securities’s Black Diamond Therapeutics BDTX Stock Holding History

SG Americas Securities’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,315
Closed -$24K – 2954
2025
Q1 		$24K Sell
15,315
-4,176
-21% -$8.76K ﹤0.01% 3361
2024
Q4 		$42K Buy
+19,491
New +$55.9K ﹤0.01% 2935
2024
Q3 		– Sell
-23,146
Closed -$108K – 3422
2024
Q2 		$108K Buy
+23,146
New +$124K ﹤0.01% 2506
2021
Q4 		– Sell
-270,458
Closed -$2.29M – 3385
2021
Q3 		$2.29M Sell
270,458
-26,852
-9% -$265K 0.01% 1140
2021
Q2 		$3.62M Buy
297,310
+275,482
+1,262% +$5.45M 0.02% 766
2021
Q1 		$530K Buy
21,828
+11,053
+103% +$298K ﹤0.01% 1991
2020
Q4 		$345K Sell
10,775
-39,550
-79% -$1.3M ﹤0.01% 2266
2020
Q3 		$1.52M Buy
50,325
+42,884
+576% +$1.31M 0.01% 934
2020
Q2 		$314K Buy
7,441
+3,176
+74% +$117K ﹤0.01% 2485
2020
Q1 		$106K Buy
+4,265
New +$130K ﹤0.01% 2961

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SG Americas Securities's BDTX Position: Q2 2025 in Review

SG Americas Securities sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 15,315 shares — an estimated $24K sold.

SG Americas Securities first reported a position in BDTX in Q1 2020 and held it in 10 quarters. The position peaked at $3.62M in Q2 2021. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • SG Americas Securities reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 15,315 Black Diamond Therapeutics shares in Q2 2025, an estimated $24K.
  • SG Americas Securities first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 10 quarters.
  • SG Americas Securities's Black Diamond Therapeutics position peaked at $3.62M in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.